Learn More
A live attenuated influenza vaccine (LAIV) is currently approved in the United States for the prevention of influenza in individuals 2-49 years of age. This article summarizes the available data describing the safety and efficacy of LAIV for the prevention of influenza in both children and adults. LAIV is administered as an intranasal spray and has been(More)
W e write this note to clarify the article " Live Attenuated Influenza Vaccine Enhances Colonization of Streptococcus pneu-moniae and Staphylococcus aureus in Mice " by Mina et al. (1) in order that patients or clinicians not misinterpret the study's clinical relevance. Mina et al. described interactions between a novel live attenuated influenza virus(More)
  • 1